We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cervical Fluid Test Developed for Gynecological Cancers

By LabMedica International staff writers
Posted on 03 Apr 2018
Print article
Image: Since fluid from the Pap test occasionally contains cells from the endometrium or ovaries, scientists found they could detect cancer cells from these organs that are present in the fluid by using different brushes (Photo courtesy of Johns Hopkins University).
Image: Since fluid from the Pap test occasionally contains cells from the endometrium or ovaries, scientists found they could detect cancer cells from these organs that are present in the fluid by using different brushes (Photo courtesy of Johns Hopkins University).
Together, endometrial and ovarian cancers account for about 25,000 deaths each year and are the third leading cause of cancer-related mortality in women in the USA. Most of these deaths are caused by high-grade tumor subtypes, which tend to metastasize before the onset of symptoms.

Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers. The new screening test called PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and potentially better outcomes for patients.

An international team of scientists working with those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) carried out a retrospective study with samples collected from 1,658 individuals, including 656 patients with endometrial or ovarian cancers and 1,002 healthy controls. The average age of 714 women without cancer who underwent Pap brush analysis was 34 (range, 17 to 67 years). The average age of 125 women without cancer who underwent Tao brush analysis was 29 (range, 18 to 74 years).

For intrauterine sampling, the Tao Brush IUMC Endometrial Sampler was used. For each sample, a single primer pair was used to amplify ~38,000 loci of LINEs throughout the genome. Massively parallel sequencing was performed on Illumina instruments. DNA from Pap brush samples, Tao brush samples, or primary tumors was amplified in three multiplex polymerase chain reactions (PCRs) with 139 primer pairs that were designed to amplify 110- to 142-bp segments. DNA from plasma was amplified in two multiplex PCRs consisting of 61 primer pairs that were designed to amplify 67- to 81-bp segments.

The investigators found that PapSEEK was nearly 99% specific for cancer, and it detected 81% of endometrial cancers and 78% were early-stage cancers and 33% of ovarian cancers and 34% were early-stage cancers. Of the 123 endometrial cancer patients studied using Tao brush samples, PapSEEK identified cancer 93% of the time. Of the 51 ovarian cancer patients studied, 45% tested positive for cancer with PapSEEK. There were no false-positive results. When the plasma and Pap brush samples were both tested, the sensitivity of the test for ovarian cancer increased to 63%.

Lucy Gilbert, M.D. MSc FRCOG, director of gynecologic oncology at McGill University Health Centre, (Montreal, QC, Canada) and a senior author of the study, said, “This allows sampling closer to where the cancers originated. Intrauterine sampling proved particularly important for increasing the detection of ovarian cancer.” The study was published on March 21, 2018, in the journal Science Translational Medicine.

Related Links:
Johns Hopkins University School of Medicine
McGill University Health Centre

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.